Lipum AB (publ) is a biopharmaceutical company specialized on a novel way to treat chronic inflammatory diseases. The lead candidate drug (SOL-116) is a fully humanized antibody designed to give safer and more efficacious therapy by blocking a previously overlooked target molecule of the immune system.
Supported by solid pre-clinical data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis Lipum is exploring a range of other diseases with a high unmet medical need. We intend to show clinical proof of concept for SOL-116. This will enable a long-term sustainable business model through strategic partnerships.
Based in Umeå, an excellent life science cluster in Sweden, Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant.
The company’s share (LIPUM) is traded on the Nasdaq First North Growth Market in Stockholm.